| 1 | (1-3)-beta-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 |
| 2 | (1-3)-ß-D-Glucan (BDG) assay (Fungitell) | - | - | - | - | 1件: 107 107 |
| 3 | BD | - | - | - | - | 2件: 28 28, 56 |
| 4 | BDMARD | - | - | - | - | 1件: 46 46 |
| 5 | BDMARD treatment | - | - | - | - | 1件: 271 271 |
| 6 | BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | 5件: Abatacept Abatacept,
Adalimumab,
Etanercept,
Golimumab,
Infliximab | 5件: D00742
D00742
,
D02597
,
D02598
,
D03203
,
D04358
| 4件: CD80 CD80,
CD86,
LTA,
TNF 💬 | 74件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
| 7 | Biological disease-modifying antirheumatic drugs (bDMARDs) | - | - | - | - | 1件: 46 46 |
| 8 | Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone | 2件: Bortezomib Bortezomib,
Dexamethasone | 2件: D00292
D00292
,
D03150
| 2件: NR3C1 NR3C1,
PSMB5 💬 | 9件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 |
| 9 | Cannabidiol Botanical Drug Substance (CBD BDS) | 1件: Cannabidiol Cannabidiol | 1件: D10915
D10915
| 2件: CNR1 CNR1,
CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |
| 10 | TETRAHYDROCANNABINOL Botanical Drug Substance (THC BDS) | 1件: Dronabinol Dronabinol | 1件: D00306
D00306
| 2件: CNR1 CNR1,
CNR2 💬 | 4件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis 💬 | 1件: 13 13 |